Marek Kwiatkowski
Corporate Officer/Principal chez QUIAPEG PHARMACEUTICALS HOLDING AB
Profil
Marek Kwiatkowski is the founder of QuiaPEG Pharmaceuticals AB, which was founded in 2012.
He held the title of Director at the company.
Currently, Dr. Kwiatkowski is a Director at Otradama & Partners AB and an Associate Professor at the University of Uppsala.
He is also a Senior Scientific Advisor at Quiapeg Pharmaceuticals Holding AB, starting in 2022.
In his former positions, Dr. Kwiatkowski was the Chief Scientific Officer & Director at Quiatech AB and the Director & Chief Scientific Officer at OLIGOvation AB.
Dr. Kwiatkowski obtained a doctorate degree from the University of Uppsala in 1984 and an undergraduate degree from Uniwersytet Jagiellonski in 1975.
Postes actifs de Marek Kwiatkowski
| Sociétés | Poste | Début |
|---|---|---|
| QUIAPEG PHARMACEUTICALS HOLDING AB | Corporate Officer/Principal | 01/01/2022 |
| University of Uppsala | Corporate Officer/Principal | - |
| Otradama & Partners AB | Directeur/Membre du Conseil | - |
Anciens postes connus de Marek Kwiatkowski
| Sociétés | Poste | Fin |
|---|---|---|
Quiatech AB
 Quiatech AB Pharmaceuticals: MajorHealth Technology Quiatech AB develops and manufactures drugs. It is a research based company that develops enabling technologies for genetic analysis, molecular diagnostics, and gene-based therapeutics in the expanding market of DNA technologies that offer significant improvements in the quality of DNA microarray and other DNA oligonucleotide data. It has also developed a new modified RNA chemistry (Qt RNA Technology) utilizing a novel 2 protecting group on the RNA amidites, this development greatly improves the synthesis conditions, producing fully functional RNA at high yields. It is headquartered in Uppsala, Sweden. | Directeur Technique/Scientifique/R&D | 30/08/2007 |
QuiaPEG Pharmaceuticals AB
 QuiaPEG Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology QuiaPEG Pharmaceuticals AB operates as biotech company developing biopharmaceuticals based on a proprietary PEGylation technology platform. The firm’s technology is applicable on proteins, peptides, and small molecules. It develops novel long-acting biopharmaceuticals for the treatment of metabolic disorders. The company was founded by Hans Marcus Bosson in 2012 and is headquartered in Solna, Sweden. | Fondateur | - |
OLIGOvation AB
 OLIGOvation AB Miscellaneous Commercial ServicesCommercial Services OLIGOvation AB develops enabling technologies for genetic analysis, molecular diagnostics and gene-based therapeutics. It offers services in the market of DNA technologies that offer improvements in the quality of DNA microarray and other DNA oligonucleotide data. The company was founded in February, 2000 and is headquartered in Uppsala, Sweden. | Directeur Technique/Scientifique/R&D | - |
Formation de Marek Kwiatkowski
| University of Uppsala | Doctorate Degree |
| Uniwersytet Jagiellonski | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| QUIAPEG PHARMACEUTICALS HOLDING AB | Health Technology |
| Entreprise privées | 4 |
|---|---|
Quiatech AB
Quiatech AB Pharmaceuticals: MajorHealth Technology Quiatech AB develops and manufactures drugs. It is a research based company that develops enabling technologies for genetic analysis, molecular diagnostics, and gene-based therapeutics in the expanding market of DNA technologies that offer significant improvements in the quality of DNA microarray and other DNA oligonucleotide data. It has also developed a new modified RNA chemistry (Qt RNA Technology) utilizing a novel 2 protecting group on the RNA amidites, this development greatly improves the synthesis conditions, producing fully functional RNA at high yields. It is headquartered in Uppsala, Sweden. | Health Technology |
OLIGOvation AB
OLIGOvation AB Miscellaneous Commercial ServicesCommercial Services OLIGOvation AB develops enabling technologies for genetic analysis, molecular diagnostics and gene-based therapeutics. It offers services in the market of DNA technologies that offer improvements in the quality of DNA microarray and other DNA oligonucleotide data. The company was founded in February, 2000 and is headquartered in Uppsala, Sweden. | Commercial Services |
QuiaPEG Pharmaceuticals AB
QuiaPEG Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology QuiaPEG Pharmaceuticals AB operates as biotech company developing biopharmaceuticals based on a proprietary PEGylation technology platform. The firm’s technology is applicable on proteins, peptides, and small molecules. It develops novel long-acting biopharmaceuticals for the treatment of metabolic disorders. The company was founded by Hans Marcus Bosson in 2012 and is headquartered in Solna, Sweden. | Health Technology |
| Otradama & Partners AB |
